Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (17670)	9/3/2005 12:35:12 PM
From: former_pgs	Respond to of 52153

Thanks Wilder, This is a rather novel and ambitious attempt, in my opinion. I'd be curious to see how this program affects pre-load / after-load in the heart. The three hallmarks of beta-adrenergic stimulation are increased L-type calcium channel activity (increase intracellular Ca2+ to increase force of contraction), phosphorylate troponin I (increase rate of muscle relaxation to allow increase in heart rate) and phosphorylate phospholamban (increase re-uptake of intracellular Ca2+ to allow increase in heart rate). The latter two would be active in the presence of this dual-acting drug, suggesting that there is a small opportunity that the force of contraction may weaken while heart rate increases. That could be trouble for patients with hypertension. I'll be following it though. It certainly looks interesting. Thanks for posting about it.